Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Paclitaxel, and Trastuzumab in HER2+ Advanced NSCLC
NCT00003881Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- May 1999
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in non-small cell lung cancer (NSCLC), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Toxicity up to 1 year. Started May 1999; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00003881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003881.